Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01669785 · ClinicalTrials.gov registry record · NA
NUPRO Sensodyne Prophylaxis Paste With NovaMin Sensitivity Relief Study
A NA study, sponsored by Dentsply International.
- Completed
- Registry status
- NA
- Development phase
- 139
- Enrollment target
NCT01669785: Completed NA study, sponsored by Dentsply International.
NCT01669785 is a NA study that has completed, run by Dentsply International. The registered enrollment target is 139 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01669785, a NA study, has completed, sponsored by Dentsply International.
- COMPLETED
- Registry status
- NA
- Development phase
- 139 participants
- Enrollment target
Study Summary
The study is intended to verify through clinical measurement that the NUPRO Sensodyne Prophylaxis Paste with Novamin provides immediate sensitivity relief as well as extended relief up to 28 days.
Primary Outcome
Pre-prophy procedure baseline assessment is measured with an electronic force sensing probe (Yeaple probe). Grams of force needed to elicit pain are recorded as hypersensitivity score for the tooth. 10,20,30,40, up to 50 grams of force are applied to the hypersensitive tooth until pain is elicited. The higher the score (the more grams of force needed to elicit a response of pain), the lower the hypersensitiv Subjects were required to have two sensitive teeth which are not adjacent to each other
Interventions
- DEVICE Group C
- DEVICE Group A
- DEVICE Group B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-05 |
| Phase | NA |
What the finished NCT01669785 record still lists
NCT01669785 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Group C is the first listed.
NCT01669785 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01669785 about?
NCT01669785 is a clinical study titled "NUPRO Sensodyne Prophylaxis Paste With NovaMin Sensitivity Relief Study". The study is intended to verify through clinical measurement that the NUPRO Sensodyne Prophylaxis Paste with Novamin provides immediate sensitivity relief as well as extended relief up to 28 days.
What is the current status of trial NCT01669785?
This trial is currently completed. It is a NA study. The enrollment target is 139 participants. The study started on 2012-03. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01669785?
The interventions under investigation include: Group C (DEVICE), Group A (DEVICE), Group B (DEVICE).
Who is sponsoring clinical trial NCT01669785?
This trial is sponsored by Dentsply International, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01669785's enrollment target sits among peer trials
139 720th of 2000 higher than 1,281 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia